IP Library › Granted Patent US 12,308,103
Granted Patent B2
US 12,308,103 · App. 17/149,611 · Granted May 20, 2025

Minimally burdensome blood glucose management for insulin-requiring diabetes

Inventor: Lane Desborough (Thousand Oaks, CA)
Assignee: Nudge BG Inc.
G16H20/17A61M5/14248A61M5/1723G05B23/0272G16H40/40G16H40/67A61M2205/18A61M2205/3584A61M2205/502A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,308,103
App. No.
17/149,611
Granted
May 20, 2025
Kind
B2
Abstract

Some embodiments include burden-free insulin delivery systems and methods. In some embodiments, a method may include receiving previous insulin delivery data at a user device from an insulin pump; receiving estimated glucose data at the user device from a continuous glucose monitor; determining an insulin delivery amount based on the previous insulin delivery data and the estimated glucose data to bring the estimated glucose data closer to a target glucose value without using any user-specific behavioral data physically entered by a user through a user interface of the user device within a previous period of time, the previous period of time being less than six hours; and communicating the insulin delivery amount to the insulin pump.

Claims (38)

1. A method comprising:

receiving previous insulin delivery data at a user device from an insulin pump;

receiving at the user device estimated glucose data from a continuous glucose monitor;

determining by the user device an insulin delivery amount based on 1) the previous insulin delivery data, 2) the estimated glucose data, and 3) user-specific behavioral data physically entered by a user through a user interface of the user device before expiration of a previous period of time to bring the estimated glucose data closer to a target glucose value, the previous period of time being three hours; and

communicating the insulin delivery amount from the user device to the insulin pump.

2. The method according to claim 1 , wherein the previous insulin delivery data includes the amount of insulin delivered to the user over a period of time.

3. The method according to claim 1 , wherein the insulin delivery data is received from the insulin pump via Bluetooth and/or the estimated glucose data is received from the continuous glucose monitor via Bluetooth.

4. The method according to claim 1 , wherein the user-specific behavioral data comprises data selected from the list consisting of one or more of a mealtime announcement, a meal carbohydrate content estimate, an exercise announcement, and a sleep announcement.

5. The method according to claim 1 , wherein the insulin delivery amount comprises an insulin correction to a basal insulin rate.

6. The method according to claim 1 , wherein the user device and the insulin pump comprise a single device.

7. A glucose management system comprising:

a glucose monitoring device;

an insulin pump;

a user interface; and

a controller in communication with the glucose monitoring device, the insulin pump, and the user interface, the controller receives previous insulin delivery data from the insulin pump, the controller receives estimated glucose data from the glucose monitoring device, the controller determines an insulin delivery amount based on 1) the previous insulin delivery data, 2) the estimated glucose data, and 3) user-specific behavioral data physically entered by a user through a user interface of the user device before expiration of a previous period of time to bring an estimated glucose data closer to a target glucose value, the previous period of time being three hours, and the controller communicates the insulin delivery amount to the insulin pump.

8. The glucose management system according to claim 7 , wherein the glucose monitoring device and the insulin pump communicate wirelessly with the controller.

9. The glucose management system according to claim 7 , wherein the glucose monitoring device is a class II insulin pump and/or the glucose monitoring device is a class II integrated continuous glucose monitoring system.

10. The glucose management system according to claim 7 , wherein the controller comprises a mobile device.

11. The glucose management system according to claim 7 , wherein the controller and the insulin pump are part of a single device.

12. The glucose management system according to claim 7 , wherein the user-specific data comprises either user-specific behavioral data or user specific physiological data.

13. The glucose management system according to claim 7 , wherein the user-specific data comprises data selected from the list consisting of one or more of a mealtime announcement, a meal carbohydrate content estimate, an exercise announcement, a sleep announcement; a glucose value, an estimated glucose value, a ketone measurement, an insulin delivery trend, physical activity data, movement data, and exertion data.

14. The glucose management system according to claim 7 ,

wherein the controller wirelessly connects with either or both the glucose monitoring device or the insulin pump;

wherein the controller determines connectivity information regarding the connection between either or both the glucose monitoring device or the insulin pump; and

wherein the controller instructs the user interface to output connectivity information.

15. The glucose management system according to claim 7 ,

wherein the controller determines a fault in the glucose management system; and

wherein the controller instructs the user interface to output a fault indication;

wherein the fault comprises a fault selected from the list consisting of a glucose monitoring device end-of-life fault, a transient fault, a permanent fault, a battery end-of-life fault, a pump fault, an occlusion, a glucose sensor pull-out fault, a controller fault, and a system operation fault.

16. The glucose management system according to claim 7 , wherein the insulin delivery amount comprises an insulin correction to a basal insulin rate.

17. A non-transitory computer-readable medium storing instructions that, when executed by a mobile computing device, cause the mobile computing device to:

receive previous insulin delivery data from an insulin pump;

receive estimated glucose data from a continuous glucose monitor;

determine an insulin delivery amount based on 1) the previous insulin delivery data, 2) the estimated glucose data, and 3) user-specific behavioral data physically entered by a user through a user interface of the user device before expiration of a previous period of time to bring the estimated glucose data closer to a target glucose value, the previous period of time being three hours; and

communicate the insulin delivery amount to the insulin pump.

18. The non-transitory computer-readable medium according to claim 17 , wherein the user-specific data comprises either user-specific behavioral data or user specific physiological data.

19. The non-transitory computer-readable medium according to claim 17 , wherein the user-specific data comprises data selected from the list consisting of one or more of a mealtime announcement, a meal carbohydrate content estimate, an exercise announcement, a sleep announcement; glucose value, an estimated glucose value, a ketone measurement, an insulin delivery trend, physical activity data, movement data, and exertion data.

20. The non-transitory computer-readable medium according to claim 17 , wherein the insulin delivery amount comprises an insulin correction to a basal insulin rate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2021
From: DESBOROUGH, LANE
To: NUDGE BG, INC.
Reel/Frame 054947/0434 →
Continuity (3)
Provisional Application 62962179 · Jan 16, 2020
Provisional Application 62962178 · Jan 16, 2020
Related Publication 20210220559A1 · Jul 22, 2021
References Cited (19)
US 9878097B2 · Estes · 2018 [cited by applicant]
US 11101030B2 · Desborough · 2021 [cited by applicant]
US 11942202B2 · Desborough · 2024 [cited by examiner]
US 20080021666A1 · Goode, Jr. et al. · 2008 [cited by applicant]
US 20090006034A1 · Hayter et al. · 2009 [cited by applicant]
US 20110184267A1 · Duke et al. · 2011 [cited by applicant]
US 20120226259A1 · Yodfat et al. · 2012 [cited by applicant]
US 20170086756A1 · Harper et al. · 2017 [cited by applicant]
US 20170189614A1 · Mazlish et al. · 2017 [cited by applicant]
US 20170203036A1 · Mazlish et al. · 2017 [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/403,518 dated Dec. 20, 2023, 9 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/736,813 dated Aug. 8, 2024, 9 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/736,825 dated Aug. 13, 2024, 11 pages. [cited by applicant]
Invitation to Pay Additional Fees as issued in connection with International Patent Application No. PCT/US2021/013496, mailed Mar. 9, 2021, 2 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/149,598 dated Mar. 30, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion as issued in connection with International Patent Application No. PCT/US2021/013496, mailed May 13, 2021, 11 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/149,598 dated May 25, 2021, 9 pages. [cited by applicant]
International Preliminary Report on Patentability as issued in connection with International Patent Application No. PCT/US2021/013496, mailed Jul. 19, 2022, 7 pages. [cited by applicant]
Non-Final Office Action in U.S. Appl. No. 17/403,518 dated Sep. 8, 2023, 18 pages. [cited by applicant]